Printer Friendly

Audentes Therapeutics Buys Cardiac Gene Therapy Specialist Cardiogen.

M2 EQUITYBITES-September 2, 2015-Audentes Therapeutics Buys Cardiac Gene Therapy Specialist Cardiogen


2 September 2015 - US-based biotechnology company Audentes Therapeutics, Inc. has acquired US-based Cardiogen Sciences, Inc., a biotechnology company focused on the discovery and development of adeno-associated virus (AAV) gene therapy products for rare, inherited arrhythmogenic diseases, Audentes said.

Terms of the deal were not disclosed.

Audentes said it plans to rapidly advance Cardiogen's lead program for the CASQ2subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT) into clinical development.

The new product candidate, designated AT003, expands Audentes' portfolio of investigational AAV gene therapy treatments for rare diseases with significant unmet medical needs, which also includes AT001 for X-Linked Myotubular Myopathy (XLMTM) and AT002 for Pompe Disease.

In addition to the CASQ2-CPVT program, the acquisition includes rights to develop and commercialize AAV gene therapy products for several additional inherited arrhythmias.

Cardiogen was founded in 2014 by Louis G. Lange, MD, PhD to translate the scientific discoveries of Dr. Silvia Priori, MD, PhD and her team at the Fondazione Salvatore Maugeri in Pavia, Italy into the development of therapeutics to address unmet medical need in inherited arrhythmias.

Lange was a founder of CV Therapeutics and as chairman, CEO and CSO, led the company through its IPO to its acquisition in 2009.

Audentes has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 2, 2015
Previous Article:Inverse Paradox Acquires Philadelphia Web Design Firm.
Next Article:Allegion Closes Acquisition of Dutch Lockmaker AXA Stenman in EUR 185m Deal.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |